Absci, AstraZeneca Join To Deliver AI-designed Antibody Against Oncology Target

(RTTNews) - Absci (ABSI) announced a collaboration with AstraZeneca to deliver an AI-designed antibody against an oncology target. Absci will contribute its generative AI technology to deliver a therapeutic candidate antibody for a specified oncology target. The deal includes an https://www.nasdaq.com/articles/absci-astrazeneca-join-to-deliver-ai-designed-antibody-against-oncology-target